133 related articles for article (PubMed ID: 16955401)
1. Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates.
Wang J; Abbas Rizvi SM; Madigan MC; Cozzi PJ; Power CA; Qu CF; Morgenstern A; Apostolidis C; Russell PJ; Allen BJ; Li Y
Prostate; 2006 Dec; 66(16):1753-67. PubMed ID: 16955401
[TBL] [Abstract][Full Text] [Related]
2. Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates.
Li Y; Abbas Rizvi SM; Blair nee Brown JM; Cozzi PJ; Qu CF; Ow KT; Tam PN; Perkins AC; Russell PJ; Allen BJ
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):896-908. PubMed ID: 15465208
[TBL] [Abstract][Full Text] [Related]
3. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).
Ballangrud AM; Yang WH; Charlton DE; McDevitt MR; Hamacher KA; Panageas KS; Ma D; Bander NH; Scheinberg DA; Sgouros G
Cancer Res; 2001 Mar; 61(5):2008-14. PubMed ID: 11280760
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters.
Song YJ; Qu CF; Rizvi SM; Li Y; Robertson G; Raja C; Morgenstern A; Apostolidis C; Perkins AC; Allen BJ
Cancer Lett; 2006 Mar; 234(2):176-83. PubMed ID: 15961220
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.
Enmon R; Yang WH; Ballangrud AM; Solit DB; Heller G; Rosen N; Scher HI; Sgouros G
Cancer Res; 2003 Dec; 63(23):8393-9. PubMed ID: 14679001
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates.
Li Y; Song E; Abbas Rizvi SM; Power CA; Beretov J; Raja C; Cozzi PJ; Morgenstern A; Apostolidis C; Allen BJ; Russell PJ
Clin Cancer Res; 2009 Feb; 15(3):865-75. PubMed ID: 19188157
[TBL] [Abstract][Full Text] [Related]
7. Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells.
Kennel SJ; Stabin M; Roeske JC; Foote LJ; Lankford PK; Terzaghi-Howe M; Patterson H; Barkenbus J; Popp DM; Boll R; Mirzadeh S
Radiat Res; 1999 Mar; 151(3):244-56. PubMed ID: 10073661
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer.
Cozzi PJ; Wang J; Delprado W; Madigan MC; Fairy S; Russell PJ; Li Y
Hum Pathol; 2006 Nov; 37(11):1442-51. PubMed ID: 16949925
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate.
Li Y; Cozzi PJ; Qu CF; Zhang DY; Abbas Rizvi SM; Raja C; Allen BJ
Cancer Lett; 2004 Mar; 205(2):161-71. PubMed ID: 15036648
[TBL] [Abstract][Full Text] [Related]
10. Targeted alpha-therapy for control of micrometastatic prostate cancer.
Li Y; Russell PJ; Allen BJ
Expert Rev Anticancer Ther; 2004 Jun; 4(3):459-68. PubMed ID: 15161444
[TBL] [Abstract][Full Text] [Related]
11. Growth and characterization of LNCaP prostate cancer cell spheroids.
Ballangrud AM; Yang WH; Dnistrian A; Lampen NM; Sgouros G
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3171s-3176s. PubMed ID: 10541360
[TBL] [Abstract][Full Text] [Related]
12. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
McDevitt MR; Barendswaard E; Ma D; Lai L; Curcio MJ; Sgouros G; Ballangrud AM; Yang WH; Finn RD; Pellegrini V; Geerlings MW; Lee M; Brechbiel MW; Bander NH; Cordon-Cardo C; Scheinberg DA
Cancer Res; 2000 Nov; 60(21):6095-100. PubMed ID: 11085533
[TBL] [Abstract][Full Text] [Related]
13. Promising tumor-associated antigens for future prostate cancer therapy.
Li Y; Cozzi PJ; Russell PJ
Med Res Rev; 2010 Jan; 30(1):67-101. PubMed ID: 19536865
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of spheroid self-assembly in liquid-overlay culture of DU 145 human prostate cancer cells.
Enmon RM; O'Connor KC; Lacks DJ; Schwartz DK; Dotson RS
Biotechnol Bioeng; 2001 Mar; 72(6):579-91. PubMed ID: 11460249
[TBL] [Abstract][Full Text] [Related]
15. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
[TBL] [Abstract][Full Text] [Related]
16. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
[TBL] [Abstract][Full Text] [Related]
17. Targeting uPA/uPAR in prostate cancer.
Li Y; Cozzi PJ
Cancer Treat Rev; 2007 Oct; 33(6):521-7. PubMed ID: 17658220
[TBL] [Abstract][Full Text] [Related]
18. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.
Yao Z; Garmestani K; Wong KJ; Park LS; Dadachova E; Yordanov A; Waldmann TA; Eckelman WC; Paik CH; Carrasquillo JA
J Nucl Med; 2001 Oct; 42(10):1538-44. PubMed ID: 11585870
[TBL] [Abstract][Full Text] [Related]
19. In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells.
Li Y; Wang J; Rizvi SM; Jager MJ; Conway RM; Billson FA; Allen BJ; Madigan MC
Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4365-71. PubMed ID: 16303921
[TBL] [Abstract][Full Text] [Related]
20. Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer.
Qu CF; Song EY; Li Y; Rizvi SM; Raja C; Smith R; Morgenstern A; Apostolidis C; Allen BJ
Clin Exp Metastasis; 2005; 22(7):575-86. PubMed ID: 16475028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
